Short answer
Sanara MedTech Inc. (SMTI) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $28M (up 8.1% year over year) with net income of −$1M.
Q3 2026 key financials · XBRL
- Revenue
- $28M
- +8.1% YoY · +1.0% QoQ
- Net income
- −$1M
- +95.4% YoY · −211.7% QoQ
- Operating margin
- 2.6%
- Gross margin
- 92.6%
Source: XBRL data from the Sanara MedTech Inc. (SMTI) Q3 2026 10-Q on SEC EDGAR. USD.
Sanara MedTech Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $28.4M, up 8% YoY from $26.3M, driven by soft tissue repair sales up 10% to $25.7M
- Gross margin approximately 93% vs 93% YoY, with bone fusion sales down 5% to $2.8M
- Net loss from continuing operations $1.3M vs $0.8M net income, Adjusted EBITDA $5.6M vs $4.9M
- Cash $16.8M vs $16.6M at December 31, 2025, operating cash flow $3.5M versus $2.8M YoY
- Outlook: cash expected to fund operations, merger costs and capital expenditures for at least 12 months; FTC Second Request extends merger review
Risk Factors
- Newly added merger risk: FTC Second Request received October 15, 2026, extending HSR waiting period until 30 days after substantial compliance
- Regulatory risk: FTC may withhold authorization or impose conditions, restrictions, or costs that delay or prevent completion
- Financial risk: Failed merger could trigger a $9,660,336 termination fee payable to MiMedx
- Operational risk: Merger uncertainty may increase employee attrition and hiring costs
- Legal risk: Shareholder litigation could impose defense costs or obtain an injunction blocking the merger
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sanara MedTech Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.